Abstract
Quantitative structure – activity relationships (QSAR) is a well established ligand-based approach to drug design. It correlates changes in the chemical structure of a series of compounds with changes in their biological activities. Peptides of equal length which bind to a certain protein are an excellent target for QSAR. In the present review, we summarize our experience in QSAR studies of peptides acting as T-cell epitopes. T-cell epitopes are protein fragments presented on the cell surface which afford the immune system the opportunity to detect and respond to both intracellular and extracellular pathogens. Epitope-based vaccines are a new generation of vaccines with lower side effects. The process of antigen presentation, which includes proteasome cleavage, TAP and MHC binding, has been modeled and analyzed by QSAR. Derived QSAR models are highly predictive, allowing us to design and test in vitro MHC superbinders. All models have been implemented in servers for in silico prediction of MHC binders and T-cell epitopes. In practice, better initial in silico prediction leads to improved subsequent experimental research on epitope-based vaccines.
Keywords: Proteasome, TAP, MHC class I, MHC class II, additive method
Current Proteomics
Title: QSAR and the Prediction of T-Cell Epitopes
Volume: 5 Issue: 2
Author(s): Irini A. Doytchinova and Darren R. Flower
Affiliation:
Keywords: Proteasome, TAP, MHC class I, MHC class II, additive method
Abstract: Quantitative structure – activity relationships (QSAR) is a well established ligand-based approach to drug design. It correlates changes in the chemical structure of a series of compounds with changes in their biological activities. Peptides of equal length which bind to a certain protein are an excellent target for QSAR. In the present review, we summarize our experience in QSAR studies of peptides acting as T-cell epitopes. T-cell epitopes are protein fragments presented on the cell surface which afford the immune system the opportunity to detect and respond to both intracellular and extracellular pathogens. Epitope-based vaccines are a new generation of vaccines with lower side effects. The process of antigen presentation, which includes proteasome cleavage, TAP and MHC binding, has been modeled and analyzed by QSAR. Derived QSAR models are highly predictive, allowing us to design and test in vitro MHC superbinders. All models have been implemented in servers for in silico prediction of MHC binders and T-cell epitopes. In practice, better initial in silico prediction leads to improved subsequent experimental research on epitope-based vaccines.
Export Options
About this article
Cite this article as:
Doytchinova A. Irini and Flower R. Darren, QSAR and the Prediction of T-Cell Epitopes, Current Proteomics 2008; 5 (2) . https://dx.doi.org/10.2174/157016408784911945
DOI https://dx.doi.org/10.2174/157016408784911945 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Peptide Biomarkers: Exploring the Diagnostic Aspect
Current Protein & Peptide Science Targeted Cancer Therapy: The Next Generation of Cancer Treatment
Current Drug Discovery Technologies Concomitant CXCR4 and CXCR7 Expression Predicts Poor Prognosis in Renal Cancer
Current Cancer Drug Targets Computational Methods and Algorithms for Mass Spectrometry Based Differential Proteomics: Recent Advances, Perspectives and Open Problems
Current Proteomics Development of DNA Methyltransferase Inhibitors for the Treatment of Neoplastic Diseases
Current Medicinal Chemistry Targeted Radionuclide Therapy of Painful Bone Metastases: Past Developments, Current Status, Recent Advances and Future Directions
Current Medicinal Chemistry Recent Updates on the Therapeutic Potential of HER2 Tyrosine Kinase Inhibitors for the Treatment of Breast Cancer
Current Cancer Drug Targets Power from the Garden: Plant Compounds as Inhibitors of the Hallmarks of Cancer
Current Medicinal Chemistry NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Current Gene Therapy Cdc20: A Potential Novel Therapeutic Target for Cancer Treatment
Current Pharmaceutical Design Lymphatic Endothelial Cells, Inflammatory Lymphangiogenesis, and Prospective Players
Current Medicinal Chemistry Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Dehydroepiandrosterone and Its Derivatives: Potentially Novel Anti-Proliferative and Chemopreventive Agents
Current Pharmaceutical Design Patented Aptamers for C-Reactive Protein Detection: A Review About their Use in Clinical Diagnostics
Recent Patents on DNA & Gene Sequences Molecular Foundations for Personalized Therapy in Prostate Cancer
Current Drug Targets Therapeutic Effects of Progesterone in Animal Models of Neurological Disorders
CNS & Neurological Disorders - Drug Targets 2-Deoxy-D-Ribose, a Downstream Mediator of Thymidine Phosphorylase, Regulates Tumor Angiogenesis and Progression
Anti-Cancer Agents in Medicinal Chemistry The Circulating Endothelial Cell in Cancer: Towards Marker and Target Identification
Current Pharmaceutical Design The Role of Clusterin in Carcinogenesis and its Potential Utility as Therapeutic Target
Current Medicinal Chemistry